CRISPR Therapeutics AG
CRSP | NASDAQ
$51.28
-$0.14 (-0.27%)
Nov 2, 2026, 10:04 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -8.11 | -9.07 | -32.27 | -4.86 | 15.25 | -28.94 |
PEG Ratio | -0.17 | -0.07 | 0.42 | 0.02 | -0.08 | 0.05 |
PS Ratio | 1.34K | 94.87 | 13.40 | 7.25K | 6.30 | 14.04K |
PB Ratio | 2.45 | 1.72 | 2.63 | 1.69 | 2.40 | 6.07 |
P/FCF Ratio | -13.63 | -22.95 | -18.38 | -5.93 | 12.59 | -39.33 |
P/OCF Ratio | -13.67 | -23.26 | -19.05 | -6.38 | 10.68 | -42.36 |
OCF/S Ratio | -9.83K | -407.93 | -70.37 | -113.7K | 59.03 | -33.15K |
Debt / Equity Ratio | 0.21 | 0.12 | 0.13 | 0.13 | 0.09 | 0.04 |
Quick Ratio | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 |
Current Ratio | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 |
Asset Turnover | 0 | 0.02 | 0.17 | 0 | 0.33 | 0 |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -30.26% | -18.96% | -8.16% | -34.67% | 15.74% | -20.96% |
Return on Assets | -25.67% | -16.34% | -6.89% | -28.99% | 13.72% | -19.08% |
Return on Invested Capital | -26.62% | -21.49% | -10.42% | -31.47% | 14.06% | -20.31% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | -6.54K% | -215% | 64.80% | -25.19K% | 88.92% | -37.37K% |
Net Profit Margin | -16.57K% | -1.05K% | -41.52% | -149.12K% | 41.36% | -48.52K% |
Pretax Profit Margin | -16.47K% | -1.04K% | -40.74% | -149.2K% | 41.57% | -48.41K% |
Operating Profit Margin | -16.19K% | -1.33K% | -60.15% | -154.39K% | 40.91% | -49.3K% |
FCF Margin | -9.86K% | -413.36% | -72.93% | -122.23K% | 50.08% | -35.71K% |
EBITDA Margin | -15.91K% | -981.16% | -35.37% | -143.65K% | 43.53% | -48.02K% |
Add to Watchlist
Select watchlists to add or remove CRSP